Kornimate/medical-research-clean huggingface dataset:
hemostatic matrix in endoscopic sinus surgery

Conditions: Sinusitis

Summary: evaluating clinical performance of hemostatic matrix with bovine thrombin in achieving hemostasis in patients undergoing endoscopic sinus surgery.


Eligibility criteria:
inclusion criteria: * patients who are 18 years or older. * patients undergoing elective primary or re-do endoscopic sinus surgery for chronic sinusitis with bleeding surface requiring an adjunct to achieve hemostasis. * patients must be willing and capable of cooperating to the extent and degree required by the protocol and sign the irb approved informed consent form prior to any participation in the study. exclusion criteria: * patients with bleeding diathesis, pathologic coagulopathy, systemic disorders, inflammatory conditions (other than chronic sinusitis or nasal polyposis) or autoimmune, immunodeficiency diseases or any other disorder that may interfere with hemostasis. * patients with severe (brisk or forceful) bleeding site(s). * patients undergoing urgent or emergency endoscopic sinus surgery. * patients with bronchial asthma who have aspirin intolerance. * patients with diffuse polyposis that would require chronic oral steroids or patients on chemotherapeutic agents that might delay healing (short term pulse steroid therapy and topical steroids are acceptable). * patients who have used anticoagulant, antiplatelet or nonsteroidal anti-inflammatory analgesic (nsaid) within 7 days prior to surgery. * patients who are morbidly obese (body mass index \> 35). * patients with acute local infection at the operative side. * patients who are current alcohol and/or drug abusers. * patients with neoplasm, craniofacial abnormalities (e.g. cleft palate), or sleep apnea using nasal cpap, or patients that may require a lothrop procedure. * female patients who are pregnant or nursing. * patients who have uncontrolled diabetes mellitus (blood glucose levels \>400 mg/dl) as determined by the investigator based on medical history. * patients who have participated in another investigational drug or device research within 30 days of enrollment. * patients with known antibodies to bovine thrombin preparations, sensitivities or religious prohibitions to porcine gelatin or bovine components.
effect of kinetic control training on flexion relaxation phenomenon and craniovertebral angle in cervical radiculopathy patients

Conditions: Cervical Radiculopathy

Summary: the purpose of the study is to determine the effect of kinetic control training on flexion relaxation phenomenon and craniovertebral angle in patients with cervical radiculopathy.

neck pain is a major health issue with high rates of recurrence. the current literature suggests people with cervical pain have altered movement control strategies and that these changes are associated with pain and disability. these altered strategies will influence the control of movement which can present as both uncontrolled translatatory movement and uncontrolled range or physiological motion. either movement dysfunction will present clinically as areas of relative flexibility (increase in translational movement) or areas of relative stiffness. changes in alignment in the cervical spine may result in a forward head posture position demonstrating an increase in low cervical flexion. the greater the forward head posture, the greater the disability. regions and segments of less mobility have been noted in the cervical spine which will present clinically as regions of relative stiffness. disturbance in neck flexor synergy has been commonly observed in patients with neck pain. this disturbed neck flexor synergy presents as altered pattern of muscle activity, where impairment in deep cervical flexors appears to be compensated by increased activity in superficial muscles (sternocleidomastoid and anterior scalene) and it is also reported that the amplitude of upper trapezius and cervical extensors have been dramatically increased among those patients. such impairments may contribute to the development of pain and disability in patients with neck pain. the kinetic control retraining strategy consists of patient education about his uncontrolled movement, retraining the coordination of movement direction control and muscle synergy retraining. movement retraining interventions that are matched to correcting specific impairments can restore movement and performance solutions, elevating movement health and the quality of life it supports.

Eligibility criteria:
inclusion criteria: 1. patients will be referred from neurologist with the diagnosis cervical spondylosis. 2. patients will be included if they have unilateral radiculopathy due to spondylotic changes of the lower cervical spine (c5-c6 and c6-c7). 3. duration of symptoms is more than three months to avoid acute stage of inflammation. 4. patient's age ranged from 40 to 55 years. 5. patients from both sexes. 6. body mass index of all patients is ranged from 25-30 kg/m2. 7. patients will be screened prior to inclusion by measuring the craniovertebral angle, if the angle was less than 50, then a participant will be referred to the study exclusion criteria: 1. spinal canal stenosis. 2. rheumatoid arthritis. 3. vertebrobasilar insufficiency. 4. spinal instability due to structural cause e.g., spondylolisthesis. 5. systemic disease (cardiovascular, infectious and/or metabolic disease that could interrupt exercises). 6. spinal tumors.
changes in grip strength by using bandage kinesio taping

Conditions: Hand Strength

Summary: the kinesio taping® method, therapeutic bandage, is another feature can be used in physical therapy, aiming to muscle enhancement, weakened muscles correction, analgesia, among others, by cutaneous stimulation of mechanoreceptors. this study aims to evaluate the efficiency of the use and effects offered by kinesio taping® method, changes in muscle strength of grip in normal subjects for clinical application.

a sample of 45 subjects will be divided randomly into three groups (g1: muscle activation technique; g2: muscle inhibition technique; g3: placebo effect) aged over 18 years male or female, where it will be initially measured the strength of grip with a dynamometer jamar® pressure. then the kinesio taping® bandage will be applied in an "i" format in the wrist flexor muscles of a dominant and non-dominant limb in g1, g2, and g3 groups. investigators will follow the application protocol suggested by method of technical. to provide the facilitation of muscle activity (g1 group) a kinesio taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. for inhibition of muscle activity (g2 group), the bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. for the control group (g3 group) the bandage will be placed from the lateral extremity to the medial axis. the measurement of grip strength was carried out in four stages: immediately before placing the kinesio taping®, 24 h, 48 h, and 72 h after its application. after collecting the data statistical investigators will held the analysis of the data.

Eligibility criteria:
inclusion criteria: * men or women aged greater than 18 years and with muscle / nerve integrity of upper limbs, hearing and responsive to verbal commands with understanding the information that aware and according to the study. exclusion criteria: * individuals who refused to participate in this research and / or do not meet the inclusion criteria.
clinical governance of patients with acute coronary syndrome in italy

Conditions: Acute Coronary Syndrome

Summary: this is a prospective, observational, multicenter study that enroll consecutive and all-comers patients hospitalized with a diagnosis of acute coronary syndrome (acs) at admission.

this is a quality improvement program which enroll all the consecutive patients hospitalized with acs. the data elements that are central to the study include the primary and secondary quality indicators (qis) that are used to define the performance and to promote improved quality of care. at least 3000 patients will be enrolled. the primary endpoint are assessed in-hospital, at admission and discharge. patients will be followed for 1 year after the acs.

Eligibility criteria:
inclusion criteria: * steacs patients: symptoms of myocardial ischemia and persistent (i.e. \> 20 min) st elevation in at least two contiguous ecg leads. n.b. positive biomarkers of cardiac necrosis (i.e. troponin) are not required to confirm the diagnosis. new or presumably new left-bundle branch block at presentation occurs infrequently, may interfere with st-elevation analysis, and should not be considered diagnostic of acute myocardial infarction (mi) in isolation. * nste-acs patients: symptoms of myocardial ischemia of at least 10 minutes without persistent st elevation in at least two contiguous ecg leads. to be included in this category patients should have at least one of the following two conditions: a) ecg evidence of nsteacs defined as t wave inversion in leads with dominant r waves of at least of at least 1 mm (100 μv) or st segment depression of at least 0.5 mm (50 μv) and/or b) biomarker evidence of nsteacs defined as at least one positive (i.e. above the 99th percentile upper reference limit) troponin value (i.e. nstemi) * a written informed consent (to agree for a contact, usually by telephone) is required only to patients who are discharged alive. exclusion criteria: * subjects who, in the opinion of the investigator, are unable to comply with study follow up procedures, including, but not limited to, patients who are in prison, who are expected to move to a remote country, or who refuse to be followed should be excluded.

Keywords: myocardial infarction quality indicator percutaneous coronary intervention unstable angina
comparison of somatosensory versus endurance-strength exercise in patients with chronic neck pain

Conditions: Neck Pain

Summary: aim: to compare the effects of somatosensory exercise vs endurance-strength exercise on the deep cervical flexor muscles on pain and perceived disability in patients with chronic neck pain. study design: protocol of a clinical trial, controlled, parallel and a blinded assessor. population: subjects aged 18 to 65 years with neck pain of 3 or more months of evolution.

the study will be carried out at the faculty of nursing and physiotherapy of the university of alcalá. a total of 60 subjects with nonspecific chronic neck pain will be selected and randomly assigned into two intervention groups. the first group will perform a somatosensory exercise program and a second group will perform activation and endurance-strength exercises of the deep cervical flexors. the duration of the intervention will be 8 weeks, with 6 sessions of physical therapy and daily home exercise. the variables pain, pressure pain threshold, disability, endurance-strength, proprioception, quality of life, kinesiophobia, quality of sleep and depression will be analyzed. measurements will be taken pre-treatment, post-treatment and a follow-up at 3 months.

Eligibility criteria:
inclusion criteria: * subjects of age between 18 and 65 years * neck pain of 3 or more months of evolution exclusion criteria: * cervical disability index less than 15/50 * infection * oncological processes * neck or arm surgery * neck or arm trauma * positive neurological signs * rheumatic diseases

Keywords: neck pain chronic pain therapeutic exercise proprioception motor control
art therapy to treat women with fibromyalgia

Conditions: Fibromyalgia

Summary: effectiveness of an art therapy program for the treatment of pain and improvements in both quality of life and body image of patients with fibromyalgia.

fibromyalgia (fm) is a chronic non-inflammatory syndrome characterized by diffuse pain throughout the body, sleep disorder, stiffness, fatigue, depression and other psychological problems. patients with fm feel incapable of performing the majority of activities of daily living. medication offers only short-term benefits. thus, it is necessary to include other measures for treatment, such as physical activity and patient education. art therapy combine the field of psychology with artistic activities, working with therapeutic and instructive aspects as well as the potential for personal growth contained in all forms of art.

Eligibility criteria:
inclusion criteria: * classification of fibromyalgia by acr criteria (wolf et al, 1990) * females * without distinction of race * age 18 to 65 years * do not have changed treatment for fibromyalgia for at least 3meses * signing the consent form exclusion criteria: * other ostearticulares rheumatic and painful * decompensated cardio-respiratory diseases * perform physical activity more than 2x a week for more than 3 months

Keywords: fibromyalgia art therapy pain quality of life body image
68ga-pentixafor pet/ct versus adrenal vein sampling in diagnosing unilateral subtype of primary aldosteronism concurrent with autonomous cortisol secretion (predict)

Conditions: Primary Aldosteronism; Autonomous Cortisol Secretion

Summary: to validate the accuracy of 68ga-pentixafor pet/ct and adrenal venous sampling (avs) in subtype diagnosis of pa/acs patients with adrenal nodules, based on biochemical and clinical remission outcomes, and to determine whether the diagnostic accuracy of 68ga-pentixafor pet/ct is non-inferior to avs.

this is a prospective, multicenter, randomized crossover trial. patients with a confirmed diagnosis of primary aldosteronism (pa) or autonomous cortisol secretion (acs) with adrenal nodules were prospectively enrolled. they were randomized to undergo 68ga-pentixafor pet/ct and adrenal venous sampling (avs) in a crossover design for subtype diagnosis. the treatment strategy was determined based on the diagnostic results, with the primary endpoint being the biochemical complete remission rate at 6 months postoperatively. the study aims to compare the value of these two methods in the subtype diagnosis of pa.

Eligibility criteria:
inclusion criteria: * getting the written informed consent; * pa conccurent with autonomous cortisol secretion; * patients with hypertension aged 18-70 years; * ct or mri scan of the adrenal glands with adenoma. exclusion criteria exclusion criteria: * unable to complete 68ga-pentixafor pet/ct or avs; * refusal of surgery or contraindications for surgery; * pa patients who meet the by-passing avs criteria \[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal ct indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \>300pg/ml\] * suspicion of familial hyperaldosteronism or liddle syndrome. \[i.e., age \<20 years, hypertension and hypokalemia, or with family history\]; * suspicion of pheochromocytoma or adrenal carcinoma; * patients with actively malignant tumor; * patients who have adrenalectomy history; * long-term use of glucocorticoids; * pregnant or lactating women; with alcohol or drug abuse and mental disorders; * congestive heart failure with new york heart association (nyha) functional classification iii or iv; history of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; severe anemia (hb\ 3 times the upper limit of normal, or estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73 m2); systemic inflammatory response syndrome (sirs); uncontrolled diabetes (fbg≥13.3 mmol/l); obesity (bmi≥35 kg/m²) or underweight (bmi≤18 kg/m²); untreated aneurysm; other comorbidity potentially interfering with treatment; * suspected pbmah or ppnad; * poor compliance or any other reason deemed unsuitable for inclusion by the investigators; * patients with adrenal insufficiency requiring hormone replacement therapy.

Keywords: primary aldosteronism autonomous cortisol secretion adrenal venous sampling 68ga-pentixafor pet/ct outcome multicenter randomized crossover trial
zr-chop in dlbcl with specific gene abnormality

Conditions: Diffuse Large B Cell Lymphoma

Summary: this is a phase 2, single center clinical trial. to evaluating the efficacy and safety of zanubrutinib in combination with r-chop in newly diagnosed diffuse large b-cell lymphoma with specific gene abnormality.

this is a phase 2, single center clinical trial. to evaluating the efficacy and safety of zanubrutinib in combination with r-chop in newly diagnosed diffuse large b-cell lymphoma with specific gene abnormality, including myc translocation, myd88 mutation, cd79b mutation, notch1 mutation and tp53 mutation. all patients received 6 cycle therapy.

Eligibility criteria:
inclusion criteria: 1. 18-75 years old; 2. histological confirmed, newly-diagnosed diffuse large b-cell lymphoma with one of the following gene abnormality including myc translocation, myd88 mutation, cd79b mutation, notch1 mutation and tp53 mutation; 3. eastern cooperative oncology group (ecog) status of 0-1; 4) hospitalized patients and received the whole cycle treatment in fudan university shanghai cancer center- 4. normal hematological, hepatic and renal function. 5. life expectancy of more than 3 months; 6. patients had at least one measurable target lesion; 7. lvef ≥ 50% 8. signed informed consent forms exclusion criteria: 1. hypersensitivity to immunoglobulin; 2. primary central nerves lymphoma 3. history of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix; 4. with contraindication of steroid including uncontrolled diabetes; 5. serious uncontrolled diseases and intercurrent infection; 6. pregnant or lactating women; 7. hepatitis b infection with hbv-dna ≥ 104

Keywords: zanubrutinib gene mutation myc translocation
phase 1 pharmacokinetic study of cp-945598 in patients with nash

Conditions: Non-Alcoholic Steatohepatitis(NASH)

Summary: cp-945598 is a potent and selective cannabinoid-1 (cb1) receptor antagonist currently being developed for the treatment of obesity. cp-945598 is also being considered as a potential treatment for non-alcoholic steatohepatitis (nash). this study will investigate the steady-state safety, toleration and pharmacokinetics of multiple oral dose administration of cp-945598. results will be used to estimate the pharmacokinetic characteristics in nash patients and underwrite the safety of this compound prior to any further studies in nash patients.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) of 25 to 40 kg/m2 * subjects with biopsy evidence of nash in the 2 years prior to the screening visit. hemoglobin ≥11 g/dl, platelet count ≥100,000 cells/mm3, neutrophil count ≥1,500cells/mm3. exclusion criteria: * other forms than nash liver disease. * decompensated or severe liver disease.

Keywords: pharmacokinetic safety nash patients
exploring the role of serum methylmalonic acid (mma) in breast cancer

Conditions: Breast Cancer

Summary: this project aims to investigate the role of mma in breast cancer. to this end, we will measure mma on serum samples collected at the time of breast cancer diagnosis, to investigate the role of mma in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty.

this project aims to investigate the role of mma in breast cancer. to this end, we will measure mma on serum samples collected at the time of breast cancer diagnosis, to investigate the role of mma in predicting long-term recurrence risk, response to neoadjuvant chemotherapy, and its association with age and clinical frailty. if the role of baseline serum mma in therapy resistance and/or metastasis is confirmed, our study could be further extended by evaluating sox4 expression in the tumor tissues (sox4 is activated by mma, and sox4 induces emt (epithelial to mesenchymal transition) and the metastasis process.

Eligibility criteria:
inclusion criteria: 1. female patients older than 18 years at diagnosis. 2. first diagnosis of invasive breast cancer. 3. all pathological parameters are available to identify histological subtype according to standard procedures. 4. availability of frozen serum samples at diagnosis. 5. voluntarily signed informed consent obtained before blood drawing for biobanking was performed. exclusion criteria: 1. pregnant at diagnosis. 2. stage 0 disease (in situ). 3. bilateral bc at diagnosis or multifocal unilateral bc with different histology. 4. other subtypes than invasive ductal carcinoma. 5. prior breast cancer.
safety and efficacy study of nh004 films for relief of sialorrhea symptoms in parkinson's disease patients

Conditions: Sialorrhea Secondary to Parkinson's Disease

Summary: the primary goal of the study is to evaluate the safety and potential efficacy of intra-oral dissolvable nh004 films to improve the short-term symptoms of sialorrhea (drooling) in parkinson's disease (pd) patients.

nh004 contains the anticholinergic agent tropicamide and is delivered in a convenient product form (intra-oral dissolvable thin films) designed for the management of sialorrhea. this study is a double blind, placebo-controlled, crossover study of the safety and potential efficacy of three doses of of nh004 films for the short-term relief of the symptoms of sialorrhea in parkinson's disease patients. a total of up to 36 parkinson's disease patients will be enrolled in the study in two phases. phase a will include 12 patients and phase b up to 24 patients. there will be an interim analysis after conclusion of phase a. in both phases patients will be randomized into one of four groups. each group will have a distinctive sequence for receiving intra-oral dissolvable films of 0.3 mg, 1 mg, 3 mg of nh004, or placebo during four visits.

Eligibility criteria:
inclusion criteria: 1. patients with idiopathic parkinson's disease, according to the united kingdom brain bank criteria. 2. patients complaining of drooling, with a score of at least 3 in the fleni sialorrhea scale. 3. patient is between 50 and 80 years of age, inclusive. 4. male or non-pregnant female. females of child-bearing potential will be required to have undergone a pregnancy test with negative results prior to entry to the study and agree to use contraceptive measures for the duration of the study. 5. patients must have used the same medication and dose for pd for the last month. no changes in the medication for pd are expected during the study. 6. patients who can reasonable be expected to be on "on-state" for the duration of the testing procedures. 7. patients who have a stable response to levodopa for pd. exclusion criteria: 1. pregnant women or women who may become pregnant. 2. patients with a diagnosis of depression, schizophrenia or with obvious symptoms of these diseases. 3. patients with mini-mental state examination (mmse) score equal to or lower than 26. 4. patients who are receiving the following drugs: tricyclic antidepressants, monoamine oxidase inhibitors (maoi's), neuroleptics (antipsychotics), or anticholinergics. 5. patients who have taken any of the drugs mentioned in exclusion criteria number 4 within the last week. 6. patients with hypersensitivity to atropine or other anticholinergic drugs. 7. patients who have experienced adverse effects as a result of taking anticholinergic drugs. 8. patients taking hypnotic or other sleep inducing drugs. 9. patients with severe urinary or gastrointestinal symptoms. 10. patients with significant dental/oral pathology. 11. patients with severe dysautonomia.

Keywords: sialorrhea drooling excessive salivation parkinson's disease